{"schema_version":"secwatch.filing_event.v1","accession":"0001093557-24-000078","form_type":"8-K","ticker":"DXCM","cik":"0001093557","company_name":"DEXCOM INC","filed_at":"2024-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.252934+00:00","generated_at":"2026-06-03T07:23:45.506292+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Dexcom Q1 revenue up 24% to $921M; GAAP EPS $0.36; updates FY guidance to $4.2-4.35B","bullets":["Revenue $921M (+24% YoY); GAAP net income $146.4M ($0.36 EPS) vs $48.6M ($0.12) in Q1 2023.","Non-GAAP operating margin 15.2% (up 460 bps YoY); Non-GAAP EPS $0.32.","FDA cleared Stelo, first OTC CGM for type 2 diabetes not on insulin; also cleared Direct-to-Watch for G7.","Updated FY2024 revenue guidance to $4.20-4.35B (17-21% organic growth); reiterated Non-GAAP gross margin ~63-64% and operating margin ~20%.","Cash $2.9B; revolving credit facility undrawn."],"urls":{"canonical":"https://secwatch.observer/filing/0001093557-24-000078","json":"https://secwatch.observer/filing/0001093557-24-000078.json","markdown":"https://secwatch.observer/filing/0001093557-24-000078.md","text":"https://secwatch.observer/filing/0001093557-24-000078.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1093557/000109355724000078/0001093557-24-000078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1093557/000109355724000078/dxcm-20240425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T07:23:45.506292+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8f5a6cb663110d83211e3c7dc308a50a3d56bbf6","claim":"DEXCOM INC reported the quarter ended March 31, 2024 results: revenue $921.0 million, net income $146.4 million, or $0.36 per diluted share, EPS $0.36 per diluted share. Guidance reaffirmed.","evidence_excerpt":"(Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2024. First Quarter 2024 Financial Highlights: • Revenue grew 24% year-over-year to $921.0 million on a reported basis and 25% year-over-year on an organic 1 basis. • U.S. revenue and international revenue both grew 24% on a reported basis and international revenue grew 26% on","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1093557/000109355724000078/0001093557-24-000078-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$921.0 million"},{"label":"Net income","value":"$146.4 million, or $0.36 per diluted share"},{"label":"EPS","value":"$0.36 per diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}